What Does CD20-Positive Mean for DLBCL Treatment and Care?

When you read that your diffuse large B-cell lymphoma (DLBCL) is “CD20-positive,” it means that your cancer cells have a specific protein called CD20 on their surface ^[1]. While seeing a “positive” result on a cancer report can be confusing, this finding simply identifies a treatment target. It tells your care team that an anti-CD20 medicine could be an important part of your treatment plan ^[2]. However, this result alone does not determine your prognosis or guarantee a cure; your expected response and exact treatment plan will depend on your lymphoma’s specific subtype, stage, molecular findings, and your overall health ^[3][4].

What is CD20?

B-cells are a type of white blood cell that normally helps your body fight infections. Because DLBCL is a cancer of these B-cells, the lymphoma cells often share many of the same characteristics as healthy B-cells ^[3].

CD20 is a structural protein that sits on the outside surface of most mature B-cells. You can think of CD20 as a specific nametag or a barcode that identifies the cell. The term “positive” on your pathology report confirms that the laboratory detected this protein on your lymphoma cells ^[1]. The vast majority of DLBCL cases are CD20-positive, though there are rare cases where it is negative, which require different treatment approaches ^[5].

The “Lock and Key” Approach to Treatment

Knowing that your cancer cells display the CD20 protein is crucial because it allows doctors to use targeted immunotherapy, most commonly a drug called rituximab ^[2]. Rituximab is a monoclonal antibody—a specialized medication engineered in a laboratory to find and attach to specific proteins.

This treatment works like a lock and key. The CD20 protein on your lymphoma cells acts as the “lock,” and rituximab is the “key.” When rituximab enters your bloodstream, it circulates until it finds the CD20 protein and securely attaches to it ^[6][7].

Once rituximab attaches to the cell, it acts like a bright flag to your body’s immune system. This tagging process helps recruit your own immune mechanisms—like healthy immune cells and macrophages—to recognize and remove the cancer cell ^[7][8]. While it does not guarantee that every single targeted cell will be eliminated, it is an important tool for controlling the disease.

How This Fits Into Your Treatment Plan

If your DLBCL is CD20-positive, many patients receive a regimen called R-CHOP as their first-line treatment ^[2]. The “R” stands for rituximab, while “CHOP” represents a combination of traditional chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine) and a steroid (prednisone). By combining targeted immunotherapy with chemotherapy, doctors can attack the cancer in different ways at the same time ^[2].

However, R-CHOP is not the only option. Your oncologist will choose your specific regimen based on your full clinical picture, including your staging work-up, heart health, age, and other genetic findings from your pathology report ^[9][10]. In rare instances, lymphoma cells can lose their CD20 protein over time, which can contribute to treatment resistance ^[1].

What CD20-Positive Does—and Does Not—Tell You

• It DOES: Identify that your cancer cells have a specific target (CD20) that can be treated with anti-CD20 drugs like rituximab ^[2].
• It DOES NOT: Tell you your cancer stage, how fast it is growing, or guarantee how well the treatment will work ^[3].

Safety and Infection Risks

Because rituximab targets the CD20 protein on most mature B-cells—including your healthy ones—your antibody protection will be reduced, temporarily increasing your risk of infections ^[9]. It does not remove every type of immune cell (for example, plasma cells are usually spared), but the depth and duration of this immune effect vary between patients.

Additionally, anti-CD20 therapy can cause dormant infections, specifically Hepatitis B, to reactivate ^[11]. Before starting treatment, your care team will run blood tests (such as HBsAg and anti-HBc) to check for current or prior Hepatitis B exposure ^[12]. If you have a history of Hepatitis B, you may need antiviral medication and specialist monitoring during and after your treatment to prevent reactivation ^[11][12]. Never start, stop, or delay any antiviral medications without your oncology team’s advice.

When to Call Your Doctor:
While receiving treatment, it is critical to monitor yourself for infection and infusion reactions. Contact your care team urgently or seek emergency care if you experience:

• A fever of 100.4°F (38.0°C) or higher
• Chills or shaking
• Sudden shortness of breath
• Confusion or feeling acutely unwell
• Symptoms of an infusion reaction during or shortly after receiving rituximab, such as sudden fever, rash, throat tightness, or dizziness.